OBT357 / MEN1112
Our lead program is the first in our collaboration with Menarini to be designated for clinical development. The product candidate is a novel enhanced antibody that incorporates BioWa’s POTELLIGENT® technology. It is designed to induce antibody-dependent cellular cytotoxicity in acute myeloid leukemia and related hematological cancers. This first-in-class therapeutic has demonstrated preclinical proof of concept by inducing the depletion of ex vivo leukemic blasts from AML patients. A Phase I AML dose-escalation study is underway.